Core Insights - Nkarta, Inc. is a clinical-stage biopharmaceutical company focused on developing engineered natural killer (NK) cell therapies [1][2] - The company will participate in two upcoming investor conferences in November 2025, including the Stifel 2025 Healthcare Conference and TD Cowen's Immunology & Inflammation Summit [1] Company Overview - Nkarta specializes in allogeneic, off-the-shelf NK cell therapies aimed at treating autoimmune diseases [2] - The company utilizes a combination of cell expansion, cryopreservation platforms, proprietary cell engineering technologies, and CRISPR-based genome engineering to develop its therapies [2] - Nkarta aims to create a pipeline of cell therapies designed for deep therapeutic activity and broad outpatient access [2]